Cargando…
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients
BACKGROUND: Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and it...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693196/ https://www.ncbi.nlm.nih.gov/pubmed/31409409 http://dx.doi.org/10.1186/s12933-019-0906-1 |
_version_ | 1783443663903260672 |
---|---|
author | Mannino, Gaia Chiara Pezzilli, Serena Averta, Carolina Fuoco, Anastasia Spiga, Rosangela Mancuso, Elettra Di Fatta, Concetta Perticone, Francesco Prudente, Sabrina Trischitta, Vincenzo Andreozzi, Francesco Sesti, Giorgio |
author_facet | Mannino, Gaia Chiara Pezzilli, Serena Averta, Carolina Fuoco, Anastasia Spiga, Rosangela Mancuso, Elettra Di Fatta, Concetta Perticone, Francesco Prudente, Sabrina Trischitta, Vincenzo Andreozzi, Francesco Sesti, Giorgio |
author_sort | Mannino, Gaia Chiara |
collection | PubMed |
description | BACKGROUND: Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and it is metabolized by the enzymes dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2. The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population. However, it is unknown whether this association holds true in T2DM patients. To address this issue, we investigated whether rs9267551 is associated with risk of myocardial infarction in two cohorts of T2DM patients. METHODS: SNP rs9267551 was genotyped in 1839 White T2DM patients from the Catanzaro Study (CZ, n = 1060) and the Gargano Heart Study-cross sectional design (GHS, n = 779). Cases were patients with a previous myocardial infarction, controls were asymptomatic patients with neither previous myocardial ischemia nor signs of it at resting and during a maximal symptom limited stress electrocardiogram. RESULTS: Carriers of allele rs9267551 C showed a dose dependent reduction in the risk of myocardial infarction [(CZ = OR 0.380, 95% CI 0.175–0.823, p = 0.014), (GHS = 0.497, 0.267–0.923, p = 0.027), (Pooled = 0.458, 0.283–0.739, p = 0.001)] which remained significant after adjusting for sex, age, BMI, smoking, HbA1c, total cholesterol HDL, and triglyceride levels [(CZ = 0.307, 0.106–0.885, p = 0.029), (GHS = 0.512, 0.270–0.970, p = 0.040), (Pooled = 0.458, 0.266–0.787, p = 0.005)]. CONCLUSIONS: We found that rs9267551 polymorphism is significantly associated with myocardial infarction in T2DM patients of European ancestry from two independent cohorts. It is possible that in subjects carrying the protective C allele less ADMA accumulates in endothelial cells causing vascular protection as a consequence of higher nitric oxide availability. |
format | Online Article Text |
id | pubmed-6693196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66931962019-08-16 A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients Mannino, Gaia Chiara Pezzilli, Serena Averta, Carolina Fuoco, Anastasia Spiga, Rosangela Mancuso, Elettra Di Fatta, Concetta Perticone, Francesco Prudente, Sabrina Trischitta, Vincenzo Andreozzi, Francesco Sesti, Giorgio Cardiovasc Diabetol Original Investigation BACKGROUND: Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and it is metabolized by the enzymes dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2. The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population. However, it is unknown whether this association holds true in T2DM patients. To address this issue, we investigated whether rs9267551 is associated with risk of myocardial infarction in two cohorts of T2DM patients. METHODS: SNP rs9267551 was genotyped in 1839 White T2DM patients from the Catanzaro Study (CZ, n = 1060) and the Gargano Heart Study-cross sectional design (GHS, n = 779). Cases were patients with a previous myocardial infarction, controls were asymptomatic patients with neither previous myocardial ischemia nor signs of it at resting and during a maximal symptom limited stress electrocardiogram. RESULTS: Carriers of allele rs9267551 C showed a dose dependent reduction in the risk of myocardial infarction [(CZ = OR 0.380, 95% CI 0.175–0.823, p = 0.014), (GHS = 0.497, 0.267–0.923, p = 0.027), (Pooled = 0.458, 0.283–0.739, p = 0.001)] which remained significant after adjusting for sex, age, BMI, smoking, HbA1c, total cholesterol HDL, and triglyceride levels [(CZ = 0.307, 0.106–0.885, p = 0.029), (GHS = 0.512, 0.270–0.970, p = 0.040), (Pooled = 0.458, 0.266–0.787, p = 0.005)]. CONCLUSIONS: We found that rs9267551 polymorphism is significantly associated with myocardial infarction in T2DM patients of European ancestry from two independent cohorts. It is possible that in subjects carrying the protective C allele less ADMA accumulates in endothelial cells causing vascular protection as a consequence of higher nitric oxide availability. BioMed Central 2019-08-13 /pmc/articles/PMC6693196/ /pubmed/31409409 http://dx.doi.org/10.1186/s12933-019-0906-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Mannino, Gaia Chiara Pezzilli, Serena Averta, Carolina Fuoco, Anastasia Spiga, Rosangela Mancuso, Elettra Di Fatta, Concetta Perticone, Francesco Prudente, Sabrina Trischitta, Vincenzo Andreozzi, Francesco Sesti, Giorgio A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title_full | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title_fullStr | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title_full_unstemmed | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title_short | A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
title_sort | functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693196/ https://www.ncbi.nlm.nih.gov/pubmed/31409409 http://dx.doi.org/10.1186/s12933-019-0906-1 |
work_keys_str_mv | AT manninogaiachiara afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT pezzilliserena afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT avertacarolina afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT fuocoanastasia afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT spigarosangela afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT mancusoelettra afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT difattaconcetta afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT perticonefrancesco afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT prudentesabrina afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT trischittavincenzo afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT andreozzifrancesco afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT sestigiorgio afunctionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT manninogaiachiara functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT pezzilliserena functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT avertacarolina functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT fuocoanastasia functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT spigarosangela functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT mancusoelettra functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT difattaconcetta functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT perticonefrancesco functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT prudentesabrina functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT trischittavincenzo functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT andreozzifrancesco functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients AT sestigiorgio functionalvariantofthedimethylargininedimethylaminohydrolase2geneisassociatedwithmyocardialinfarctionintype2diabeticpatients |